TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04179071
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive famotidine tablet 40mg orally after an overnight (minimum 8hours) of fasting.
Study: NCT02588625
Drug: BMS-986020
Normalized name: BMS-986020
DrugBank: BMS-986020 (DB14948)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04090567
Drug: Cediranib
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04090567
Drug: Ceralasertib
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04090567
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04388033
Drug: Interleukin-12
Normalized name: interleukin-12
DrugBank: Edodekin alfa (DB15631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given subcutaneously at dose of 6ug twice for interval of one hour.
Study: NCT04388033
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Following concomitant radiation (2 Gy/day x 30 days) and TMZ-chemotherapy (75 mg/m2/ day x 42 days) , maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.
Study: NCT01862328
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (IV) in a 21-day cycle:~* Paclitaxel on Day 1 of each cycle
Study: NCT01862328
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (IV) in participants in a 28-day cycle:~-Gemcitabine on Days 1,8,15 of each cycle
Study: NCT01862328
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (IV) in participants in a 21-day cycle:~- Docetaxel on Day 1 of each cycle
Study: NCT01862328
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (IV) in participants in a 21-day cycle:~- Carboplatin on Day 1 of each cycle
Study: NCT00989079
Drug: Ertugliflozin
Normalized name: Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.
Study: NCT00467584
Drug: High Dose Aspirin (1300 mg/day)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1300 milligrams per day (the equivalent of 4 regular aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
Study: NCT00467584
Drug: Low Dose Aspirin (162 mg/day)
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 162 milligrams per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
Study: NCT04284917
Drug: Carglumic Acid (Carbaglu®)
Normalized name: Carglumic Acid
DrugBank: Carglumic acid (DB06775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A. Study period: 36 months; treatment period: 12 months.~B. Patients will receive Carglumic Acid (Carbaglu®) 50 mg/kg/day in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12).~C. Patients need to regularly come back for follow up examination on Day 0, month 3, month 6, and month 12.~D. Patients should report any adverse event that occur during treatment period.~E. Patients' number of emergency visits due to hyperammonemia, ammonia level, acylcarnitine, urinary organic acid analysis, plasma amino acid analysis and methylmalonic acid will be recorded during treatment period.
Study: NCT03775265
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03775265
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03775265
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03775265
Drug: Mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03498066
Drug: Beta-blockers withdrawal
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: withdrawal of all type of betablockers
Study: NCT00547196
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00547196
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03291977
Drug: Fluorescéine Sodique Faure
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorescéine Sodique Faure given intravenously during the induction of the anesthesia, at the dose of 3mg/kg, diluted in 50mL of physiological serum, in 10 minutes.
Study: NCT00547196
Drug: Fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00547196
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00547196
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03443869
Drug: Letermovir
Normalized name: Letermovir
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: LET 480mg (or 240 mg when administered concomitantly with cyclosporin A) once daily for 28 weeks
Study: NCT03443869
Drug: Valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 900 mg VGCV tablet orally, once daily for 28 weeks
Study: NCT03443869
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg over-encapsulated ACV tablet orally, every 12 hours for 28 weeks
Study: NCT03443869
Drug: Placebo to ACV
Normalized name: ACV tripeptide
DrugBank: ACV tripeptide (DB02025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-encapsulated placebo tablet orally, every 12 hours for 28 weeks
Study: NCT02778178
Drug: ropivacaine plus clonidine
Normalized name: Clonidine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
Study: NCT02099461
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single sucutaneous dose
Study: NCT01483872
Drug: Standard anticoagulant (Heparin or Citrate)
Normalized name: ANTICOAGULANT CITRATE DEXTROSE
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00576199
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab was supplied as a sterile liquid in single-use vials.
Study: NCT03776851
Drug: erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: erythropoietin 50 International Units (IU) per kilogram three times weekly by subcutaneous route
Study: NCT03091166
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02262832
Drug: Metreleptin
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: administered subcutaneously 1-2 times/day
Study: NCT00748007
Drug: Rivastigmine
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Exelon (1.5mg/cap) 1.5 mg bid
Study: NCT01118728
Drug: Sarilumab
Normalized name: Sarilumab
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT00215982
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered at a dose of 130 mg/m2 IV over 120 minutes in 250-500 ML D5W on day 1, every 42 days.
Study: NCT00215982
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan will be administered at a dose of 180mg/m2 IV over 90 minutes on day 21 every 42 days.
Study: NCT01983020
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01983020
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02233790
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a loading dose of 180mg pre-PCI, and then 90 mg twice daily for 1 Month within the study. Thereafter, the patients will take clopidogrel if Ticagrelor is not available on the market.
Study: NCT02233790
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg once daily after a loading dose of 300 mg pre-PCI.
Study: NCT00851045
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution, IV, 180 mg/m2, Q14 days, Until PD
Study: NCT00851045
Drug: 5-Fluorouracil (bolus)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution, IV, 400 mg/m2, Q14 days, Until PD
Study: NCT00851045
Drug: CT-322
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, IV, 2 mg/kg, Q7 days, Until PD
Study: NCT00851045
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solutions, IV, 5 mg/kg, Q14 days, Until PD
Study: NCT00851045
Drug: Bevacizumab Placebo (saline solution)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution, IV, 0 mg/kg, On day 8 of a 2-week cycle, Until PD
Study: NCT00955747
Drug: Tagatose
Normalized name: Tagatose
DrugBank: Tagatose (DB04936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: powder; 15 grams three times daily; one year
Study: NCT00955747
Drug: Sugar Substitute Splenda
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g powder tid
Study: NCT03623256
Drug: Spinal bupivacaine
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route.
Study: NCT03623256
Drug: Spinal Fentanyl and Bupivacaine
Normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL), and 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
Study: NCT03623256
Drug: Epidural fentanyl /spinal bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route, and 100 mcg of fentanyl (2 mL) will be administered by epidural route.
Study: NCT00634179
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib 1.6 mg/m² given on days 1 and 8
Study: NCT00634179
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine 1.4 mg/m² (capped at 1.5 mg maximum) given on day 1
Study: NCT00634179
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 100 mg/day given orally on days 1-5
Study: NCT03349606
Drug: d-amphetamine
Normalized name: d-amphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral d- amphetamine 0.5 mg/kg is used to stimulate dopamine release in the brain
Study: NCT03804645
Drug: Treatment C
Normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive single dose of AZD9977 ODL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and other dose under fasted condition.
Study: NCT03804645
Drug: Treatment D
Normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will receive single dose of AZD9977 tablet under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
Study: NCT03234673
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 sessions of fractional CO2 laser one month apart Patients will start treatment Tarolimus ointment twice daily for 3 months.
Study: NCT03234673
Drug: calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 sessions of fractional CO2 laser one month apart Patients will start treatment Calcipotriol ointment twice daily for 3 months.
Study: NCT03234673
Drug: NB-UVB
Normalized name: Nb
DrugBank: Niobium (DB13031)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 sessions of fractional CO2 laser one month apart Patients will start treatment NB-UVB phototherapy twice weekly for 3 months
Study: NCT00331864
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02260492
Drug: OT329 (combination of fluticasone propionate and salmeterol xinafoate)
Normalized name: Fluticasone Propionate and Salmeterol Inhalation Powder
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Solis dry powder inhaler
Study: NCT02260492
Drug: Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)
Normalized name: Advair
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Diskus dry powder inhaler
Study: NCT02402868
Drug: Ketamine and saline
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine intravenous and intranasal
Study: NCT02022501
Drug: DE-120
Normalized name: Glucagon like peptide-1 Elastin like peptide-120 fusion protein
DrugBank: Froniglutide (DB16178)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02669680
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF subcutaneously, 5 μg/kg daily on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses
Study: NCT00395707
Drug: Lucentis
Normalized name: Lucentis
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.3mg/0.05 ml or 0.5mg/0.05 ml
Study: NCT00395707
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.3mg/0.05 ml or 0.5mg/0.05 ml
Study: NCT00395707
Drug: Ranibizumab (Lucentis)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.3mg/0.05 ml intravitreally
Study: NCT00395707
Drug: Ranibizumab (Lucentis)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5mg/0.05 ml
Study: NCT00824460
Drug: Sevelamer hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).
Study: NCT02078063
Drug: Mepivacaine
Normalized name: Mepivacaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
Study: NCT00222677
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg daily
Study: NCT03604692
Drug: axatilimab
Normalized name: Axatilimab
DrugBank: Axatilimab (DB16388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: axatilimab is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor derived macrophages that mediate the disease processes involved in cGVHD.
Study: NCT02818361
Drug: Topical tripterygium gel
Normalized name: Tripterygium wilfordii whole extract
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00185562
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04295551
Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,
Study: NCT04295551
Drug: Lopinavir/ritonavir treatment
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization
Study: NCT03899259
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT01237821
Drug: BenzaClin
Normalized name: Benzaclin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks
Study: NCT01237821
Drug: Effaclar
Normalized name: Effaclar K
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical, Bid, 12 weeks
Study: NCT03191721
Drug: Triclosan toothpaste
Normalized name: sodium fluoride / triclosan Toothpaste
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dental brushing with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.
Study: NCT03191721
Drug: Fluoride toothpaste
Normalized name: sodium fluoride Toothpaste
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental brushing with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.
Study: NCT04316858
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90ml of sodium phosphate will be added to 800ml of solvent( water or zero calorie carbonated drink) and taken in divided doses one day prior to procedure. Whole solution will be finished 3 -4 hours before colonoscopy.
Study: NCT02542293
Drug: Paclitaxel + carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy Agents
Study: NCT02542293
Drug: Gemcitabine + cisplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy Agents
Study: NCT02542293
Drug: Gemcitabine + carboplatin
Normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy Agents
Study: NCT02542293
Drug: Pemetrexed + cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy Agent
Study: NCT02542293
Drug: Pemetrexed + carboplatin
Normalized name: Carboplatin
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy Agent
Study: NCT03779191
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Alectinib dosed 600 mg twice a day (BID) with meals until disease progression, unacceptable toxicity, or other reasons specified in the protocol
Study: NCT03779191
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
Study: NCT00003557
Drug: dolastatin 10
Normalized name: Dolastatin 10
DrugBank: Dolastatin 10 (DB12730)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03780829
Drug: D-cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NMDA agonist treatment
Study: NCT03780829
Drug: sham-NMDA agonist
Normalized name: NMDA
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sham-NMDA agonist treatment
Study: NCT00261079
Drug: Fexofenadine
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04223583
Drug: Anlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard first-line chemotherapy regimen (adriamycin + ifosfamide) failed
Study: NCT00191906
Drug: Atomoxetine Hydrochloride
Normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
Study: NCT02342444
Drug: Enoxaparin Sodium Injection 30 mg BID
Normalized name: enoxaparin sodium Injectable Solution
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02342444
Drug: Enoxaparin Sodium Injection 40 mg QD
Normalized name: Enoxaparin Sodium Injection
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01411267
Drug: AC220
Normalized name: Quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
Study: NCT01411267
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age